CARLOMAGNO, Simona
 Distribuzione geografica
Continente #
NA - Nord America 109
AS - Asia 63
EU - Europa 42
AF - Africa 15
Totale 229
Nazione #
US - Stati Uniti d'America 103
SG - Singapore 59
IT - Italia 25
TG - Togo 15
CA - Canada 6
GB - Regno Unito 4
BE - Belgio 3
DE - Germania 3
NL - Olanda 3
HK - Hong Kong 2
LT - Lituania 2
CH - Svizzera 1
CN - Cina 1
IE - Irlanda 1
IN - India 1
Totale 229
Città #
Singapore 49
Boardman 46
Lomé 15
Ogden 14
Tavagnacco 5
London 4
New York 4
Toronto 4
Brussels 3
Frankfurt am Main 3
Genoa 3
Trieste 3
Udine 3
Amsterdam 2
Codroipo 2
Ferrandina 2
Hong Kong 2
Los Angeles 2
Ottawa 2
Pittsburgh 2
Santa Clara 2
Beijing 1
Buffalo 1
Columbus 1
Dublin 1
Hyderabad 1
Monte San Giusto 1
Naples 1
Rome 1
Salerno 1
Zurich 1
Totale 182
Nome #
CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma 19
Ultrastructural and cytofluorimetric analyses of blood-derived human NK cells cultured under metastatic-calcification-like conditions 14
CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells 13
NK Cell-Based Immunotherapy in Colorectal Cancer 13
De novo expression of CCR7 and acquisition of migratory properties by human KIR2DS1+ NK cells interacting with allogeneic HLA-C2+ monocyte-derived DC or T cell blasts 11
Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly (I:C) in human NK cells derived from different donors 11
The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells 11
De novo expression of CCR7 and acquisition of migratory properties by human KIR2DS1+ NK cells interacting with allogeneic HLA-C2+ monocyte-derived DC or T cell blasts 10
Bridging innate NK cell Functions with Adaptive Immunity 10
KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DC or T cell blasts 10
Natural Killer cells expressing the KIR2DS1 activating receptor efficiently kill T cell blasts and dendritic cells: implications in haploidentical HSCT 10
Features of Memory-Like and PD-1+ Human NK Cell Subsets 10
An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More 9
Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells 8
Human NK cell response to pathogens 8
The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function 8
Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes (LDGL) 8
Identification of a novel cord blood NK cell subpopulation expressing functional programmed death receptor-1 8
NK/DC crosstalk in anti-viral response 8
KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DC or T cell blasts 8
NK cells and their receptors during viral infections 8
miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy 7
Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly (I:C) in human NK cells derived from different donors 7
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia 7
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells 7
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment 7
Different features of tumor-associated NK cells in patients with low-grade or high-grade peritoneal carcinomatosis 7
Activating KIRs and NKG2C in viral infections: Toward NK cell memory? 7
Natural killer cells expressing the KIR2DS1 activating receptor efficiently kill T cell blasts and dendritic cells: implications in haploidentical HSCT 7
Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer 7
KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DC or T cell blasts 6
Natural killer cell impairment in ovarian clear cell carcinoma 6
KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing 6
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2 6
NK Cell-Based Immunotherapy for Hematological Malignancies 6
Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation 6
Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2 6
Uptake of CCR7 by KIR2DS4⁺ NK cells is induced upon recognition of certain HLA-C alleles 6
The tryptophan catabolite L-Kynurenine affects human NK cell function 6
Pancreatic ductal adenocarcinoma microenvironment: Soluble factors and cancer associated fibroblasts as modulators of NK cell functions 5
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles 5
KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DC or T cell blasts 5
TLR/NCR/KIR: Which One to Use and When? 5
The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors 5
Role of the main non HLA-specific activating NK receptors in pancreatic, colorectal and gastric tumors surveillance 5
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor 5
Natural killer lymphocytes: "null cells" no more 4
Totale 371
Categoria #
all - tutte 6.005
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.005


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024205 0 142 2 2 0 5 0 5 22 25 1 1
2024/2025166 10 51 31 16 58 0 0 0 0 0 0 0
Totale 371